BR112012023315A2 - compostos inibidores de enzima - Google Patents
compostos inibidores de enzimaInfo
- Publication number
- BR112012023315A2 BR112012023315A2 BR112012023315A BR112012023315A BR112012023315A2 BR 112012023315 A2 BR112012023315 A2 BR 112012023315A2 BR 112012023315 A BR112012023315 A BR 112012023315A BR 112012023315 A BR112012023315 A BR 112012023315A BR 112012023315 A2 BR112012023315 A2 BR 112012023315A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibiting compounds
- enzyme inhibiting
- compounds
- enzyme
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 abstract 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 abstract 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1004311.5A GB201004311D0 (en) | 2010-03-15 | 2010-03-15 | New enzyme inhibitor compounds |
| PCT/EP2011/053818 WO2011113798A2 (en) | 2010-03-15 | 2011-03-14 | New enzyme inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012023315A2 true BR112012023315A2 (pt) | 2016-05-24 |
Family
ID=42261625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012023315A BR112012023315A2 (pt) | 2010-03-15 | 2011-03-14 | compostos inibidores de enzima |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9227967B2 (https=) |
| EP (2) | EP2927233A1 (https=) |
| JP (2) | JP5643347B2 (https=) |
| KR (1) | KR20130057971A (https=) |
| CN (1) | CN103180319A (https=) |
| AU (1) | AU2011229267B2 (https=) |
| BR (1) | BR112012023315A2 (https=) |
| CA (1) | CA2793125A1 (https=) |
| DK (1) | DK2547677T3 (https=) |
| EA (1) | EA023038B1 (https=) |
| ES (1) | ES2538526T3 (https=) |
| GB (1) | GB201004311D0 (https=) |
| MX (1) | MX2012010292A (https=) |
| NZ (1) | NZ602141A (https=) |
| SG (1) | SG183936A1 (https=) |
| WO (1) | WO2011113798A2 (https=) |
| ZA (1) | ZA201206424B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9290499B2 (en) | 2010-05-19 | 2016-03-22 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| GB201115853D0 (en) * | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
| IN2014DN01883A (https=) * | 2011-09-14 | 2015-05-15 | Proximagen Ltd | |
| MX2014004086A (es) | 2011-10-03 | 2014-09-22 | Univ North Carolina | Compuestos de pirrolopirimidina para el tratamiento del cancer. |
| AU2013255103B2 (en) | 2012-05-02 | 2016-09-29 | Syntara Limited | Substituted 3-haloallylamine inhibitors of SSAO and uses thereof |
| AU2013266438B2 (en) | 2012-05-22 | 2017-09-07 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
| WO2014026330A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| EP2909211A4 (en) | 2012-10-17 | 2016-06-22 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
| GB201304527D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| US9555031B2 (en) | 2014-04-11 | 2017-01-31 | The University Of North Carolina At Chapel Hill | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity |
| WO2015188368A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
| GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| GB201416446D0 (en) * | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
| KR102412146B1 (ko) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
| GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
| WO2017098236A1 (en) | 2015-12-07 | 2017-06-15 | Proximagen Limited | Vap-1 inhibitors for treating pain |
| US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| CN106045876B (zh) * | 2016-06-07 | 2018-02-09 | 四川福思达生物技术开发有限责任公司 | 一种对氯苯肼盐酸盐的合成方法 |
| AU2017326006B2 (en) * | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories |
| US20250066308A1 (en) * | 2021-10-01 | 2025-02-27 | Yuhan Corporation | Bicyclic fused ring derivative or salt thereof and pharmaceutical composition comprising same |
| US12110276B2 (en) | 2021-11-24 | 2024-10-08 | Genentech, Inc. | Pyrazolo compounds and methods of use thereof |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| US20250197392A1 (en) * | 2022-04-08 | 2025-06-19 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992006979A1 (de) * | 1990-10-15 | 1992-04-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue diazine |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| PL354514A1 (en) | 1999-09-14 | 2004-01-26 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as d4 |
| AU2002214505A1 (en) | 2000-11-09 | 2002-05-21 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives |
| US6982286B2 (en) | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| WO2003029209A2 (en) | 2001-10-02 | 2003-04-10 | Smithkline Beecham Corporation | Chemical compounds |
| MY126268A (en) | 2001-11-07 | 2006-09-29 | Schering Corp | Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
| US7456169B2 (en) | 2003-02-27 | 2008-11-25 | Abbott Laboratories Inc. | Heterocyclic kinase inhibitors |
| WO2005014530A2 (en) | 2003-08-08 | 2005-02-17 | La Jolla Pharmaceutical Co. | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases |
| ES2319539T3 (es) | 2003-09-17 | 2009-05-08 | Janssen Pharmaceutica Nv | Compuestos heterociclicos condensados como moduladores del receptor de serotonina. |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| WO2006114180A1 (de) * | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
| PT1906965E (pt) | 2005-06-22 | 2015-09-03 | Chemocentryx Inc | Compostos de azaindazol e métodos de utilização |
| US20070293548A1 (en) | 2006-03-31 | 2007-12-20 | Wang Eric Y | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases |
| BRPI0710527B8 (pt) | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| EP2078004B1 (en) | 2006-10-31 | 2015-02-25 | Merck Sharp & Dohme Corp. | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors |
| AU2007329548A1 (en) | 2006-12-06 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| WO2008088744A1 (en) | 2007-01-17 | 2008-07-24 | Merck & Co., Inc. | Decahydroquinoline analogs as cb2 receptor modulators |
| EP2152716A1 (en) | 2007-05-02 | 2010-02-17 | Novartis Ag | Heterocyclic compounds and their use as pesticides |
| GB0725103D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
| CA2712701A1 (en) | 2008-01-31 | 2009-08-06 | Henning Steinhagen | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| WO2009108551A2 (en) * | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| DK2334672T3 (da) | 2008-09-16 | 2013-12-02 | Proximagen Ltd | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridinforbindelser som inhibitorer af SSAO |
| US8633318B2 (en) * | 2008-09-16 | 2014-01-21 | Proximagen Ltd | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder |
| EP2376490B1 (en) | 2008-12-04 | 2013-01-23 | Proximagen Limited | Imidazopyridine compounds |
| JP2012211085A (ja) | 2009-08-12 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | ヘッジホッグシグナル阻害剤 |
-
2010
- 2010-03-15 GB GBGB1004311.5A patent/GB201004311D0/en not_active Ceased
-
2011
- 2011-03-14 NZ NZ602141A patent/NZ602141A/en not_active IP Right Cessation
- 2011-03-14 JP JP2012557516A patent/JP5643347B2/ja not_active Expired - Fee Related
- 2011-03-14 CA CA2793125A patent/CA2793125A1/en not_active Abandoned
- 2011-03-14 MX MX2012010292A patent/MX2012010292A/es not_active Application Discontinuation
- 2011-03-14 ES ES11707689.3T patent/ES2538526T3/es active Active
- 2011-03-14 SG SG2012066023A patent/SG183936A1/en unknown
- 2011-03-14 CN CN2011800140213A patent/CN103180319A/zh active Pending
- 2011-03-14 DK DK11707689.3T patent/DK2547677T3/en active
- 2011-03-14 BR BR112012023315A patent/BR112012023315A2/pt not_active IP Right Cessation
- 2011-03-14 AU AU2011229267A patent/AU2011229267B2/en not_active Ceased
- 2011-03-14 EP EP15158284.8A patent/EP2927233A1/en not_active Withdrawn
- 2011-03-14 WO PCT/EP2011/053818 patent/WO2011113798A2/en not_active Ceased
- 2011-03-14 KR KR1020127025301A patent/KR20130057971A/ko not_active Withdrawn
- 2011-03-14 EA EA201290880A patent/EA023038B1/ru not_active IP Right Cessation
- 2011-03-14 US US13/634,732 patent/US9227967B2/en not_active Expired - Fee Related
- 2011-03-14 EP EP20110707689 patent/EP2547677B1/en not_active Not-in-force
-
2012
- 2012-08-27 ZA ZA2012/06424A patent/ZA201206424B/en unknown
-
2014
- 2014-10-30 JP JP2014221061A patent/JP2015017141A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG183936A1 (en) | 2012-10-30 |
| JP2015017141A (ja) | 2015-01-29 |
| ES2538526T3 (es) | 2015-06-22 |
| ZA201206424B (en) | 2013-06-26 |
| EA201290880A1 (ru) | 2013-03-29 |
| US9227967B2 (en) | 2016-01-05 |
| AU2011229267A1 (en) | 2012-09-20 |
| MX2012010292A (es) | 2013-03-12 |
| US20130102587A1 (en) | 2013-04-25 |
| KR20130057971A (ko) | 2013-06-03 |
| CA2793125A1 (en) | 2011-09-22 |
| EA023038B1 (ru) | 2016-04-29 |
| AU2011229267B2 (en) | 2013-07-18 |
| EP2547677B1 (en) | 2015-05-06 |
| JP2013529179A (ja) | 2013-07-18 |
| GB201004311D0 (en) | 2010-04-28 |
| JP5643347B2 (ja) | 2014-12-17 |
| NZ602141A (en) | 2014-09-26 |
| CN103180319A (zh) | 2013-06-26 |
| EP2927233A1 (en) | 2015-10-07 |
| EP2547677A2 (en) | 2013-01-23 |
| DK2547677T3 (en) | 2015-06-01 |
| WO2011113798A3 (en) | 2011-11-17 |
| WO2011113798A2 (en) | 2011-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012023315A2 (pt) | compostos inibidores de enzima | |
| BR112014005581A2 (pt) | compostos inibidores de enzima | |
| CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
| MX2010009416A (es) | Compuestos heterociclicos como inhibidores de cxcr2. | |
| EA201492210A1 (ru) | Соединения, ингибирующие активность катехол-o-метилтрансферазы | |
| MY167126A (en) | Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | |
| BR112017012707A2 (pt) | compostos inibidores de parg | |
| MX2009005829A (es) | Polialquileniminas hidrofobicamente modificadas para usarse como inhibidores de transferencia de colorante. | |
| BR112014003693A2 (pt) | amino quinazolinas como inibidores de quinase | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| BR112013004517A2 (pt) | derivados de triazolopirazina | |
| BR112012019561A2 (pt) | hetarilamino naftiridinas | |
| CR20140128A (es) | Inhibidores de la enzima activadora de nedd 8 | |
| PH12016502534A1 (en) | Azaquinazoline carboxamide derivatives | |
| MX2015013365A (es) | Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag). | |
| BR112014016803A2 (pt) | amidas macrocíclicas como inibidoras de protease | |
| BR112015012411A2 (pt) | derivado de hidantoína | |
| BR112013005689A2 (pt) | método para produção de compostos de piridazinona e intermediário dos mesmos | |
| MX2015013374A (es) | Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag). | |
| BR112012003616A8 (pt) | Metilpirrolopirimidinacarboxamidas | |
| BR112015023280A2 (pt) | derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase | |
| BR112013024361A2 (pt) | novos compostos de azaspirodecanona como inibidores de hsl | |
| BRPI0920959A2 (pt) | Inibidores de glicogênio sintase quinase-3 beta contendo derivados de 7-hidróxi-benzoimidazol-4-il-metanona | |
| MX2014008856A (es) | Derivados de imidazolilcetona como inhibidores de aldosterona sintasa. | |
| MX2015016961A (es) | Derivados de urea macrociclicos como inhibidores de tafia, su preparacion y su uso como productos farmaceuticos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |